Delineating Between Pathophysiologic Phenotypes of Hypoxic Ischemic Brain Injury After Cardiac Arrest
Launched by UNIVERSITY OF BRITISH COLUMBIA · May 23, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the brain gets oxygen after a person has had a cardiac arrest, which is when the heart stops beating. Researchers have found that some patients struggle to get enough oxygen into their brains even when more oxygen is delivered through the blood. This trial aims to identify patients who have normal versus abnormal oxygen transport in their brains and to understand why some people have these issues. Understanding these differences could help improve care for patients after a cardiac arrest.
To participate in the trial, individuals must be over 19 years old, have experienced a cardiac arrest with a Glasgow Coma Scale score of 8 or lower (which measures consciousness), and have had invasive monitoring set up within 72 hours of the cardiac arrest. Additionally, their cardiac arrest must have lasted longer than 10 minutes. People with certain medical conditions or those currently taking specific medications may not be eligible. Participants can expect a series of evaluations to assess how well their brains are receiving oxygen, which could help shape future treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Greater than 19 years old post cardiac arrest with a Glasgow Coma Scale of 8 or less
- • 2) Invasive monitoring implemented within 72 hours of cardiac arrest
- • 3) Duration of cardiac arrest greater than 10 minutes.
- Exclusion Criteria:
- • 1) Coagulopathy (INR \> 1.5, PTT \> 40, Platelets \< 100x106 per microliter)
- • 2) Current or anticipated use of anticoagulant or antiplatelet medication
- • 3) Target temperature under 35oC; 4) history of severe TBI, intracranial hemorrhage or stroke.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials